A murine model study revealed that sustaining the premetastatic phenotype of pancreatic ductal adenocarcinoma (PADC) requires sustained expression of p53 R172H, which increases platelet-derived growth factor beta (PDGFR), and inhibition of PDGFR with imatinib significantly prevents PDAC metastasis in vivo [103]. Here, PDGFRB is linked to pancreatic ductal adenocarcinoma.